Search results
Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
Zacks via Yahoo Finance· 8 hours agoGilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 1 day agoThe company also unveiled promising results in people age 18 to 59 years old with underlying...
Health Care Roundup: Market Talk
The Wall Street Journal· 1 day agoFind insight on GSK, Top Glove, ResMed and more in the latest Market Talks covering the Health Care sector.
Gilead’s Twice-Yearly Shot Prevents HIV. Where the Stock Is Headed.
Barrons.com· 1 day agoIts older medicine, Truvada, is available as an inexpensive generic. ViiV Healthcare, an HIV-focused...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 1 day agoUsually, RSV causes coldlike symptoms in most people. But in newborns and older adults it can be...
Industry groups back drugmakers' appeal in Zantac cancer lawsuits
Reuters· 1 day ago, opens new tab and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued...
Postdoc to investigate molecular mechanisms in the field immune-rejuvenation for drug discovery -...
Nature· 4 days agoIn the compelling and unstoppable research in favor of cellular rejuvenation, Sentcell LTD is looking for PhD or Postdoc Researchers to investigate molecular mechanisms and innovative therapies ...
Arcturus Therapeutics appoints Moncef Slaoui to board By Investing.com
Investing.com· 1 day agoInc. (NASDAQ:ARCT), a biotechnology company specializing in mRNA medicines for infectious diseases...
As big pharma exits Nigeria, asthma patients face spiralling costs
Al Jazeera· 2 days agoWhen Gloria Mofifoluwa’s friend informed her in March that the price of inhalers had risen in...
Paris may be 'one Olympics too early' for Team GB fears athletics legend
Daily Express· 7 days agoWith only eight weeks to go, you have got to be thinking the positive stuff. You don’t want negative...
